查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494793

到 2030 年甲状腺癌诊断的全球市场预测：按产品、癌症类型、测试类型、癌症阶段、诊断技术、最终用户和地区进行分析

Thyroid Cancer Diagnostics Market Forecasts to 2030 - Global Analysis By Product (Assay Kits, Instruments, Reagents, Consumables and Other Products), Cancer Type, Test Type, Cancer Stage, Diagnostic Technique, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球甲状腺癌诊断市场规模为 28.2 亿美元，预计在预测期内将以 5.6% 的复合年增长率增长，到 2030 年达到 93.7 亿美元。

甲状腺癌诊断涉及一系列医学评估和测试，以检测和表征甲状腺癌。这些诊断工具可以帮助确定甲状腺癌的存在、类型和阶段，并指导适当的治疗策略。早期发现可以及时介入并改善治疗结果和存活率。准确的诊断有助于临床医生製定适当的治疗计划，最大限度地减少不必要的手术并降低医疗成本。

据美国癌症协会称，2021 年可能会发现约 44,280 例新的甲状腺癌病例。

越来越重视客製化治疗

个人化医疗策略强调准确的诊断，以识别与癌症相关的特定基因突变和生物标记。这需要使用先进的诊断技术，例如分子测试和基因组分析。因此，医疗保健提供者越来越依赖全面的诊断方法来准确表征甲状腺癌亚型，并能够根据患者的个别需求制定治疗方法。这一趋势透过促进先进诊断技术的采用，推动了甲状腺癌诊断市场的扩张。

误报和过度诊断

假阳性可能导致不必要的切片检查、手术和治疗，给患者带来身体和情绪上的痛苦。过度诊断会导致进行性和非进行性癌症进行不必要的标记和治疗，进一步导致医疗资源紧张。这削弱了人们对诊断测试和治疗的信心，并阻止患者和医疗保健提供者使用它们，从而阻碍了该领域的市场扩张和创新。

加大医疗基础建设投资

增加对医疗保健基础设施的投资将改善获得先进诊断技术和服务的机会。对现代医疗设施、设备和培训的投资将使医疗保健提供者能够更准确、更及时地诊断甲状腺癌。改善基础设施也有助于早期发现和治疗，从长远来看可以改善患者的治疗效果并降低医疗成本。此外，医疗基础设施的扩张将促进研究和开发，促进技术创新和新诊断方法的引入，进一步刺激市场成长。

昂贵的测试和技术

由于其复杂性和特异性，甲状腺癌的诊断通常需要昂贵的测试和技术。先进的成像技术、分子测试和切片检查程序导致了高昂的成本。这些费用可能会阻碍患者及时寻求诊断和治疗，特别是在医疗保健资源有限或保险覆盖范围不足的地区。此外，高成本可能导致医疗保健预算紧张，限制诊断服务的获取，并阻碍市场成长。

COVID-19 的影响

COVID-19 的爆发扰乱了医疗保健服务，包括例行检查和择期手术的延误，从而影响了甲状腺癌诊断市场。随着患者前往医疗机构就诊的次数减少，并且资源被用于对抗这场流行病，诊断检测量也有所减少。然而，远端医疗以及医疗保健业务的逐步恢復正常业务预计将支持疫情后的市场復苏。

预计临床前诊断领域在预测期内将是最大的。

预计晚期诊断领域将出现良好的成长。晚期甲状腺癌的诊断着重准确、全面的评估，以指导治疗计画。这使得医疗保健提供者能够根据癌症的特异性特征量身定制治疗计划，从而实现更个人化和标靶治疗。整体而言，晚期甲状腺癌的准确诊断有助于改善预后、生活品质和整体医疗资源利用率。

预计诊断影像在预测期内将表现出最高的复合年增长率

预计诊断成像在预测期内将经历最高的复合年增长率。癌症诊断影像使用多种技术，包括 MRI、 电脑断层扫描、PET 扫描、超音波和分子影像，以可视化肿瘤并评估其特征、大小、位置和转移潜力。这些非侵入性方法可以帮助早期发现癌症、分期、规划治疗并监测其进展。功能和分子成像等疗法提供了对肿瘤生物学的深入了解，并指导个人化治疗方法以改善患者的治疗结果。

比最大的地区

由于甲状腺癌发病率上升、医疗基础设施改善以及早期检测意识不断增强，预计亚太地区将在预测期内占据最大的市场占有率。中国、印度和日本等国家人口众多且医疗保健系统发达，导致诊断测试的需求激增。此外，诊断技术的进步和政府改善癌症护理的倡议正在进一步推动市场扩张。

复合年增长率最高的地区：

由于甲状腺癌发病率增加、诊断技术的进步以及早期检测意识的提高，预计北美在预测期内将呈现最高的复合年增长率。该市场受益于强大的医疗基础设施和对研发的大量投资。此外，精准医疗和个人化医疗保健的日益普及也推动了该地区的市场扩张。美国和加拿大是这一市场成长的主要贡献者。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球甲状腺癌诊断市场：副产品

  • 检测套件
  • 装置
  • 试剂
  • 消耗品
  • 其他产品

第六章全球甲状腺癌诊断市场：依癌症类型分类

  • 甲状腺乳突癌
  • 滤泡性甲状腺癌
  • 甲状腺髓样癌
  • 未分化甲状腺癌
  • 其他癌症类型

第七章全球甲状腺癌诊断市场：依测试类型

  • 诊断测试
  • 监控检查

第八章全球甲状腺癌诊断市场：依癌症阶段划分

  • 早期诊断
  • 晚期诊断

第九章全球甲状腺癌诊断市场：依诊断技术分类

  • 影像
  • 验血
  • 分子诊断
  • 切片检查
  • 其他诊断技术

第10章全球甲状腺癌诊断市场：依最终用户分类

  • 诊断实验室
  • 学术研究所
  • 专科诊所
  • 医院

第十一章全球甲状腺癌诊断市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Abbott Laboratories
  • Roche Limited
  • Thermo Fisher Scientific
  • Siemens Healthcare
  • Bio-Rad Laboratories
  • General Electric
  • Koninklijke Philips NV
  • Toshiba Corporation
  • Agilent Technologies
  • Illumina Inc.
  • BioMerieux SA
  • Biocare Medical LLC
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • PerkinElmer Inc.
  • Quest Diagnostics Incorporated
  • Bayer AG
Product Code: SMRC26308

According to Stratistics MRC, the Global Thyroid Cancer Diagnostics Market is accounted for $2.82 billion in 2024 and is expected to reach $9.37 billion by 2030 growing at a CAGR of 5.6% during the forecast period. Thyroid cancer diagnostics involve a series of medical evaluations and tests to detect and characterize thyroid cancer. These diagnostic tools help determine the presence, type, and stage of thyroid cancer, guiding appropriate treatment strategies. Early detection enables timely intervention, improving treatment outcomes and survival rates. Accurate diagnosis helps clinicians tailor appropriate treatment plans, minimizing unnecessary procedures and reducing healthcare costs.

According to the American Cancer Society, about 44,280 new thyroid cancer patients may be detected in 2021.

Market Dynamics:

Driver:

Growing focus on tailored treatment plans

Personalized medicine strategies emphasize the importance of precise diagnosis to identify specific genetic mutations or biomarkers associated with the cancer. This necessitates the use of sophisticated diagnostic techniques such as molecular testing and genomic analysis. Consequently, healthcare providers increasingly rely on comprehensive diagnostic approaches to accurately characterize thyroid cancer subtypes, enabling them to tailor treatment regimens according to individual patient needs. This trend fuels the expansion of the thyroid cancer diagnostics market by driving adoption of advanced diagnostic technologies.

Restraint:

False positives and over diagnosis

False positives can lead to unnecessary biopsies, surgeries, and treatments, causing physical and psychological distress to patients. Over diagnosis can result in the unnecessary labeling and treatment of indolent or non-progressive cancers, further burdening healthcare resources. This undermines confidence in diagnostic tests and treatments, discouraging both patients and healthcare providers from utilizing them, thereby impeding market expansion and innovation in the field.

Opportunity:

Increased investments in healthcare infrastructure

Increased investments in healthcare infrastructure enhance access to advanced diagnostic technologies and services. Investments in modern medical facilities, equipment, and training enable healthcare providers to offer more accurate and timely diagnosis of thyroid cancer. Improved infrastructure also facilitates early detection and treatment, leading to better patient outcomes and reduced healthcare costs in the long term. Moreover, expanded healthcare infrastructure fosters research and development, driving innovation and the introduction of new diagnostic methods, further stimulating market growth.

Threat:

Expensive tests and technologies

Thyroid cancer diagnostics often involve expensive tests and technologies due to their complexity and specialized nature. Advanced imaging techniques, molecular testing, and biopsy procedures contribute to high costs. These expenses can deter patients from seeking timely diagnosis and treatment, particularly in regions with limited healthcare resources or inadequate insurance coverage. Moreover, high costs may strain healthcare budgets, limiting access to diagnostic services and impeding market growth.

Covid-19 Impact

The covid-19 pandemic has influenced the thyroid cancer diagnostics market by causing disruptions in healthcare services, including delays in routine screenings and elective procedures. Reduced patient visits to healthcare facilities and reallocation of resources towards managing the pandemic have led to a decline in diagnostic testing volumes. However, increased emphasis on telemedicine and the gradual return to normal healthcare operations are expected to support market recovery post-pandemic.

The advanced-stage diagnosis segment is expected to be the largest during the forecast period

The advanced-stage diagnosis segment is estimated to have a lucrative growth. Advanced-stage thyroid cancer diagnosis focuses on precise and comprehensive evaluation to guide treatment plans. It enables healthcare providers to tailor treatment plans according to the specific characteristics of the cancer, leading to more personalized and targeted therapies. Overall, accurate thyroid cancer diagnostics in advanced stages contribute to better prognosis, quality of life, and overall healthcare resource utilization.

The imaging segment is expected to have the highest CAGR during the forecast period

The imaging segment is anticipated to witness the highest CAGR growth during the forecast period. Imaging cancer diagnostics employ various techniques such as MRI, CT scans, PET scans, ultrasound, and molecular imaging to visualize tumours and assess their characteristics, size, location, and potential metastasis. These non-invasive methods aid in early detection, staging, treatment planning, and monitoring of cancer progression. Advancements like functional and molecular imaging provide insights into tumor biology, guiding personalized treatment approaches for improved patient outcomes.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period due to rising incidences of thyroid cancer, improving healthcare infrastructure, and increasing awareness about early detection. Countries like China, India, and Japan are witnessing a surge in demand for diagnostic tests driven by their large population bases and evolving healthcare systems. Moreover, advancements in diagnostic technologies and government initiatives to improve cancer care further fuel market expansion.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, driven by increasing thyroid cancer incidence, advancements in diagnostic technologies, and rising awareness about early detection. The market benefits from strong healthcare infrastructure and significant investments in research and development. Additionally, the growing adoption of precision medicine and personalized healthcare approaches further propels market expansion in this region. The United States and Canada are the primary contributors to this market growth.

Key players in the market

Some of the key players profiled in the Thyroid Cancer Diagnostics Market include Abbott Laboratories, Roche Limited, Thermo Fisher Scientific, Siemens Healthcare, Bio-Rad Laboratories, General Electric, Koninklijke Philips N.V., Toshiba Corporation, Agilent Technologies, Illumina Inc., BioMerieux SA, Biocare Medical LLC, Danaher Corporation, F. Hoffmann-La Roche AG, PerkinElmer Inc., Quest Diagnostics Incorporated and Bayer AG.

Key Developments:

In April 2024, Bio-Rad Laboratories, Inc. launched the ddPLEX ESR1 Mutation Detection Kit, its first ultrasensitive multiplexed digital PCR assay for breast cancer mutation detection in clinical research. The assay is designed for Bio-Rad's QX600(TM) Droplet Digital(TM) PCR and can detect, discriminate, and quantify key mutations in the ESR1 gene for breast cancer.

In March 2024, Bayer AG and Thermo Fisher Scientific Inc. announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.

Products Covered:

  • Assay Kits
  • Instruments
  • Reagents
  • Consumables
  • Other Products

Cancer Types Covered:

  • Papillary Thyroid Cancer
  • Follicular Thyroid Cancer
  • Medullary Thyroid Cancer
  • Anaplastic Thyroid Cancer
  • Other Cancer Types

Test Types Covered:

  • Diagnostic Tests
  • Monitoring Tests

Cancer Stages Covered:

  • Early-Stage Diagnosis
  • Advanced-Stage Diagnosis

Diagnostic Techniques Covered:

  • Imaging
  • Blood Tests
  • Molecular Diagnostics
  • Biopsy
  • Other Diagnostic Techniques

End Users Covered:

  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Specialty Clinics
  • Hospitals

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Thyroid Cancer Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Assay Kits
  • 5.3 Instruments
  • 5.4 Reagents
  • 5.5 Consumables
  • 5.6 Other Products

6 Global Thyroid Cancer Diagnostics Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Papillary Thyroid Cancer
  • 6.3 Follicular Thyroid Cancer
  • 6.4 Medullary Thyroid Cancer
  • 6.5 Anaplastic Thyroid Cancer
  • 6.6 Other Cancer Types

7 Global Thyroid Cancer Diagnostics Market, By Test Type

  • 7.1 Introduction
  • 7.2 Diagnostic Tests
  • 7.3 Monitoring Tests

8 Global Thyroid Cancer Diagnostics Market, By Cancer Stage

  • 8.1 Introduction
  • 8.2 Early-Stage Diagnosis
  • 8.3 Advanced-Stage Diagnosis

9 Global Thyroid Cancer Diagnostics Market, By Diagnostic Technique

  • 9.1 Introduction
  • 9.2 Imaging
  • 9.3 Blood Tests
  • 9.4 Molecular Diagnostics
  • 9.5 Biopsy
  • 9.6 Other Diagnostic Techniques

10 Global Thyroid Cancer Diagnostics Market, By End User

  • 10.1 Introduction
  • 10.2 Diagnostic Laboratories
  • 10.3 Academic & Research Institutes
  • 10.4 Specialty Clinics
  • 10.5 Hospitals

11 Global Thyroid Cancer Diagnostics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 Roche Limited
  • 13.3 Thermo Fisher Scientific
  • 13.4 Siemens Healthcare
  • 13.5 Bio-Rad Laboratories
  • 13.6 General Electric
  • 13.7 Koninklijke Philips N.V.
  • 13.8 Toshiba Corporation
  • 13.9 Agilent Technologies
  • 13.10 Illumina Inc.
  • 13.11 BioMerieux SA
  • 13.12 Biocare Medical LLC
  • 13.13 Danaher Corporation
  • 13.14 F. Hoffmann-La Roche AG
  • 13.15 PerkinElmer Inc.
  • 13.16 Quest Diagnostics Incorporated
  • 13.17 Bayer AG

List of Tables

  • Table 1 Global Thyroid Cancer Diagnostics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Thyroid Cancer Diagnostics Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Thyroid Cancer Diagnostics Market Outlook, By Assay Kits (2022-2030) ($MN)
  • Table 4 Global Thyroid Cancer Diagnostics Market Outlook, By Instruments (2022-2030) ($MN)
  • Table 5 Global Thyroid Cancer Diagnostics Market Outlook, By Reagents (2022-2030) ($MN)
  • Table 6 Global Thyroid Cancer Diagnostics Market Outlook, By Consumables (2022-2030) ($MN)
  • Table 7 Global Thyroid Cancer Diagnostics Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 8 Global Thyroid Cancer Diagnostics Market Outlook, By Cancer Type (2022-2030) ($MN)
  • Table 9 Global Thyroid Cancer Diagnostics Market Outlook, By Papillary Thyroid Cancer (2022-2030) ($MN)
  • Table 10 Global Thyroid Cancer Diagnostics Market Outlook, By Follicular Thyroid Cancer (2022-2030) ($MN)
  • Table 11 Global Thyroid Cancer Diagnostics Market Outlook, By Medullary Thyroid Cancer (2022-2030) ($MN)
  • Table 12 Global Thyroid Cancer Diagnostics Market Outlook, By Anaplastic Thyroid Cancer (2022-2030) ($MN)
  • Table 13 Global Thyroid Cancer Diagnostics Market Outlook, By Other Cancer Types (2022-2030) ($MN)
  • Table 14 Global Thyroid Cancer Diagnostics Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 15 Global Thyroid Cancer Diagnostics Market Outlook, By Diagnostic Tests (2022-2030) ($MN)
  • Table 16 Global Thyroid Cancer Diagnostics Market Outlook, By Monitoring Tests (2022-2030) ($MN)
  • Table 17 Global Thyroid Cancer Diagnostics Market Outlook, By Cancer Stage (2022-2030) ($MN)
  • Table 18 Global Thyroid Cancer Diagnostics Market Outlook, By Early-Stage Diagnosis (2022-2030) ($MN)
  • Table 19 Global Thyroid Cancer Diagnostics Market Outlook, By Advanced-Stage Diagnosis (2022-2030) ($MN)
  • Table 20 Global Thyroid Cancer Diagnostics Market Outlook, By Diagnostic Technique (2022-2030) ($MN)
  • Table 21 Global Thyroid Cancer Diagnostics Market Outlook, By Imaging (2022-2030) ($MN)
  • Table 22 Global Thyroid Cancer Diagnostics Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 23 Global Thyroid Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2022-2030) ($MN)
  • Table 24 Global Thyroid Cancer Diagnostics Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 25 Global Thyroid Cancer Diagnostics Market Outlook, By Other Diagnostic Techniques (2022-2030) ($MN)
  • Table 26 Global Thyroid Cancer Diagnostics Market Outlook, By End User (2022-2030) ($MN)
  • Table 27 Global Thyroid Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 28 Global Thyroid Cancer Diagnostics Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 29 Global Thyroid Cancer Diagnostics Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 30 Global Thyroid Cancer Diagnostics Market Outlook, By Hospitals (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.